HIV Treatment Innovation Module 2: Management of Common Comorbidities for People Living with HIV

Support Statement

This program has been supported by an independent educational grant from Theratechnologies Inc.
This program has continued support from Gilead Inc.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from HealthHIV, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.

Faculty Disclosures

David Alain Wohl, MD
Professor of Medicine in the Division of Infectious Diseases
University of North Carolina, School of Medicine Co-Principal Investigator
Global UNC Infectious Diseases Clinical Trial Unit Site Leader
HIV Prevention and Treatment Clinical Trials Unit
Chapel Hill, NC

Disclosure: David Wohl, MD has a relevant financial relationship with the following eligible companies: Serve/served as an advisor/consultant/independent contractor to Gilead Sciences, Viiv, Merck, EMD Serono, Regeneron, and Theratechnologies.

Receives Research Support from these ineligible companies (research funding by principal or named investigator): Gilead, Viiv and Merck.

All relevant financial relationships have been disclosed and mitigated in accordance with Joint Accreditation standards and HealthHIV internal policy.

Disclosure and Conflict of Interest Policy

HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 80% or higher is needed to obtain credit.  Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at [email protected].

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 80% or higher is needed to obtain MOC credit (80% is required for ABS).

For Pharmacists, HealthHIV  will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This Activity

HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV. 

The materials presented here are used with the permission of the authors and/or other sources. 

If you have any questions related to educational credits, including the type or amount of credit awarded, reporting of credits to certifying boards, or general accreditation-related inquiries, please contact the Accreditation Team at [email protected]. A member of our team will be happy to assist you.

If you are experiencing issues accessing or downloading your certificate of completion, or if you have questions specifically about your individual certificate, please reach out directly to Beth at [email protected].